{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:10:51Z","timestamp":1769166651146,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Special Anti-epidemic Project of Provincial Department of Education in Zhejiang University","award":["Y202043493"],"award-info":[{"award-number":["Y202043493"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Chronic myelomonocytic leukemia (CMML) is a rare and aggressive myeloid malignancy with overlapped features of myelodysplastic syndromes\/myeloproliferative neoplasms. Azacitidine (AZA), a hypomethylating agent, has been approved for the treatment of CMML in China, but real-world data are limited.\u00a0Medical records of CMML patients who had received subcutaneously injected AZA were reviewed from January 2018 at five participating sites in China. Response was assessed according to the modified International Working Group (IWG 2006) criteria.\u00a0Between January 2018 and November 2020, a total of 24 patients with CMML were included with a median age of 63\u00a0years. Patients received a median of 3 cycles of AZA treatment (range, 1\u20138). Overall response rate (ORR) was 37.5% (9 of 24); CR rate, PR rate, and mCR\/HI rate were 8.3% (n\u2009=\u20092), 8.3% (n\u2009=\u20092), and 20.8% (n\u2009=\u20095), respectively. At a median duration of follow-up of 14.0\u00a0months (range 0.0\u201322.0\u00a0months), the median overall survival (OS) was 23.0\u00a0months. Univariate analysis revealed that\u2009\u2265\u20093 cycles of treatment was significantly associated with a higher 1-year OS rate compared with\u2009&lt;\u20093 cycles of AZA treatment. Treatment was generally well-tolerated. The most common (&gt;\u200910%) AEs were thrombocytopenia (n\u2009=\u20097, 29.2%), pneumonitis (n\u2009=\u20094, 16.7%) and fever (n\u2009=\u20093, 12.5%). This study provides valuable real-life data in China on the treatment schedules, efficacy and safety of AZA in the treatment of CMML.<\/jats:p>","DOI":"10.1007\/s10637-022-01283-x","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:03:03Z","timestamp":1657782183000},"page":"1117-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study"],"prefix":"10.1007","volume":"40","author":[{"given":"Yu","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangsen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"1283_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"1283_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"1283_CR3","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","volume":"16","author":"C Ricci","year":"2010","unstructured":"Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F (2010) RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 16:2246\u20132256. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2112","journal-title":"Clin Cancer Res"},{"key":"1283_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","volume":"38","author":"E Schuler","year":"2014","unstructured":"Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kundgen A, Hildebrandt B, Haas R, Gattermann N, Germing U (2014) Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res 38:1413\u20131419. https:\/\/doi.org\/10.1016\/j.leukres.2014.09.003","journal-title":"Leuk Res"},{"key":"1283_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","volume":"87","author":"JM Bennett","year":"1994","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87:746\u2013754. https:\/\/doi.org\/10.1111\/j.1365-2141.1994.tb06734.x","journal-title":"Br J Haematol"},{"key":"1283_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.14061","volume":"174","author":"SA Srour","year":"2016","unstructured":"Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, Dores GM (2016) Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312. Br J Haematol 174:382\u2013396. https:\/\/doi.org\/10.1111\/bjh.14061","journal-title":"Br J Haematol"},{"key":"1283_CR7","first-page":"1400","volume":"91","author":"KJ Phekoo","year":"2006","unstructured":"Phekoo KJ, Richards MA, Moller H, Schey SA, South Thames Haematology Specialist Committee (2006) The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 91:1400\u20131404","journal-title":"Haematologica"},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11899-019-00509-9","volume":"14","author":"H Elmariah","year":"2019","unstructured":"Elmariah H, DeZern AE (2019) Chronic myelomonocytic leukemia: 2018 update to prognosis and treatment. Curr Hematol Malig Rep 14:154\u2013163. https:\/\/doi.org\/10.1007\/s11899-019-00509-9","journal-title":"Curr Hematol Malig Rep"},{"key":"1283_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","volume":"130","author":"E Solary","year":"2017","unstructured":"Solary E, Itzykson R (2017) How I treat chronic myelomonocytic leukemia. Blood 130:126\u2013136. https:\/\/doi.org\/10.1182\/blood-2017-04-736421","journal-title":"Blood"},{"key":"1283_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","volume":"95","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Tefferi A (2020) Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol 95:97\u2013115. https:\/\/doi.org\/10.1002\/ajh.25684","journal-title":"Am J Hematol"},{"key":"1283_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00277-021-04539-3","volume":"100","author":"JS Gonzalez","year":"2021","unstructured":"Gonzalez JS, Perusini MA, Basquiera AL, Alfonso G, Fantl D, Lima WM, Nucifora E, Lazzarino C, Novoa V, de Andrade Silva MC et al (2021) Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients. Ann Hematol 100:1439\u20131449. https:\/\/doi.org\/10.1007\/s00277-021-04539-3","journal-title":"Ann Hematol"},{"key":"1283_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.25104","volume":"93","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Tefferi A (2018) Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol 93:824\u2013840. https:\/\/doi.org\/10.1002\/ajh.25104","journal-title":"Am J Hematol"},{"key":"1283_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/CCO.0000000000000337","volume":"29","author":"A Alfonso","year":"2017","unstructured":"Alfonso A, Montalban-Bravo G, Garcia-Manero G (2017) Current management of patients with chronic myelomonocytic leukemia. Curr Opin Oncol 29:79\u201387. https:\/\/doi.org\/10.1097\/CCO.0000000000000337","journal-title":"Curr Opin Oncol"},{"key":"1283_CR14","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Ades L, Fenaux P, Beyne-Rauzy O et al (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428\u20132436. https:\/\/doi.org\/10.1200\/JCO.2012.47.3314","journal-title":"J Clin Oncol"},{"key":"1283_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E et al (2016) Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 128:1408\u20131417. https:\/\/doi.org\/10.1182\/blood-2016-05-714030","journal-title":"Blood"},{"key":"1283_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH et al (2015) An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 5:e333. https:\/\/doi.org\/10.1038\/bcj.2015.53","journal-title":"Blood Cancer J"},{"key":"1283_CR17","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A et al (2013) Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 27:1504\u20131510. https:\/\/doi.org\/10.1038\/leu.2013.88","journal-title":"Leukemia"},{"key":"1283_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00277-017-3064-0","volume":"96","author":"P Niscola","year":"2017","unstructured":"Niscola P, Tendas A, Abruzzese E, Caravita T, Cupelli L, Giovannini M, Scaramucci L, Siniscalchi A, Trawinska MM, de Fabritiis P (2017) Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. Ann Hematol 96:1591\u20131593. https:\/\/doi.org\/10.1007\/s00277-017-3064-0","journal-title":"Ann Hematol"},{"key":"1283_CR19","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/s2352-3026(20)30374-4","volume":"8","author":"L Pleyer","year":"2021","unstructured":"Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P et al (2021) Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol 8:e135\u2013e148. https:\/\/doi.org\/10.1016\/s2352-3026(20)30374-4","journal-title":"Lancet Haematol"},{"key":"1283_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8\u201313. https:\/\/doi.org\/10.1002\/ijc.23607","journal-title":"Int J Cancer"},{"key":"1283_CR21","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/1535-7163.mct-08-0411","volume":"7","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Bokelmann I, Mahlknecht U, Lyko F (2008) Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7:2998\u20133005. https:\/\/doi.org\/10.1158\/1535-7163.mct-08-0411","journal-title":"Mol Cancer Ther"},{"key":"1283_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223\u2013232. https:\/\/doi.org\/10.1016\/s1470-2045(09)70003-8","journal-title":"Lancet Oncol"},{"key":"1283_CR23","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/jco.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429\u20132440. https:\/\/doi.org\/10.1200\/jco.2002.04.117","journal-title":"J Clin Oncol"},{"key":"1283_CR24","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/leu.2014.85","volume":"28","author":"MW Drummond","year":"2014","unstructured":"Drummond MW, Pocock C, Boissinot M, Mills J, Brown J, Cauchy P, Cross NC, Hartley S, Kell J, Szubert A et al (2014) A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia 28:1570\u20131572. https:\/\/doi.org\/10.1038\/leu.2014.85","journal-title":"Leukemia"},{"key":"1283_CR25","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/jco.2015.66.2510","volume":"35","author":"MA Sekeres","year":"2017","unstructured":"Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D et al (2017) Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745\u20132753. https:\/\/doi.org\/10.1200\/jco.2015.66.2510","journal-title":"J Clin Oncol"},{"key":"1283_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ajh.25488","volume":"94","author":"T Coston","year":"2019","unstructured":"Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N et al (2019) Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol 94:767\u2013779. https:\/\/doi.org\/10.1002\/ajh.25488","journal-title":"Am J Hematol"},{"key":"1283_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","volume":"36","author":"M Thorpe","year":"2012","unstructured":"Thorpe M, Montalv\u00e3o A, Pierdomenico F, Moita F, Almeida A (2012) Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 36:1071\u20131073. https:\/\/doi.org\/10.1016\/j.leukres.2012.04.024","journal-title":"Leuk Res"},{"key":"1283_CR28","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1002\/cncr.25759","volume":"117","author":"R Costa","year":"2011","unstructured":"Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J (2011) Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 117:2690\u20132696. https:\/\/doi.org\/10.1002\/cncr.25759","journal-title":"Cancer"},{"key":"1283_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1080\/10428194.2018.1540783","volume":"60","author":"PT Diamantopoulos","year":"2019","unstructured":"Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E et al (2019) Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leuk Lymphoma 60:1721\u20131730. https:\/\/doi.org\/10.1080\/10428194.2018.1540783","journal-title":"Leuk Lymphoma"},{"key":"1283_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655316","volume":"11","author":"A Montanino","year":"2021","unstructured":"Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V, Costanzo R, Sandomenico C, Botti G, Piccirillo MC et al (2021) Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol 11:655316. https:\/\/doi.org\/10.3389\/fonc.2021.655316","journal-title":"Front Oncol"},{"key":"1283_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425. https:\/\/doi.org\/10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"1283_CR32","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA, Cancer, Leukemia Group B","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA, Cancer, Leukemia Group B (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895\u20133903. https:\/\/doi.org\/10.1200\/JCO.2005.05.4346","journal-title":"J Clin Oncol"},{"key":"1283_CR33","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1002\/cncr.25774","volume":"117","author":"LR Silverman","year":"2011","unstructured":"Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF (2011) Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117:2697\u20132702. https:\/\/doi.org\/10.1002\/cncr.25774","journal-title":"Cancer"},{"key":"1283_CR34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/cncr.24894","volume":"116","author":"P Musto","year":"2010","unstructured":"Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V (2010) Azacitidine for the treatment of lower risk myelodysplastic syndromes\u202f: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 116:1485\u20131494. https:\/\/doi.org\/10.1002\/cncr.24894","journal-title":"Cancer"},{"key":"1283_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","volume":"38","author":"L Pleyer","year":"2014","unstructured":"Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A et al (2014) Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res 38:475\u2013483. https:\/\/doi.org\/10.1016\/j.leukres.2014.01.006","journal-title":"Leuk Res"},{"key":"1283_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","volume":"37","author":"L Ad\u00e8s","year":"2013","unstructured":"Ad\u00e8s L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P et al (2013) Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 37:609\u2013613. https:\/\/doi.org\/10.1016\/j.leukres.2013.01.004","journal-title":"Leuk Res"},{"key":"1283_CR37","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.3109\/10428194.2016.1138295","volume":"57","author":"SK Tantravahi","year":"2016","unstructured":"Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (2016) A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza(R)) in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 57:2441\u20132444. https:\/\/doi.org\/10.3109\/10428194.2016.1138295","journal-title":"Leuk Lymphoma"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01283-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:50:02Z","timestamp":1678510202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01283-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01283-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Approval number [2020-IIT573]).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived given the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}